Table of Content

1. Introduction to Peptide Therapeutics
1.1 Overview of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Significance of Peptides as Cancer Therapeutics


2. Global Cancer Peptide Therapeutics Market Insight
2.1 Current Market Scenario
2.2 Global Cancer Peptide Therapeutics Market Forecast


3. Global Peptide Cancer Therapeutics Market Trend By Region
3.1 Japan
3.2 South Korea
3.3 China
3.4 Australia
3.5 US
3.6 Europe


4. Marketed Cancer Peptides Drugs Insight – Availability, Cost, Dosage, Indication & Patent Insight
4.1 Firmagon (Degarelix)
4.2 Eligard (Leuprolide)
4.3 Lupron (Leuprolide Acetate)
4.4 Supprelin LA (Histrelin Acetate)
4.5 Gonax (Degarelix Acetate)
4.6 Trelstar (Triptorelin)
4.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
4.8 Velcade (Bortizomib)
4.9 Ninlaro (Ixazomib)
4.10 Kyprolis (Carfilzomib)
4.11 Istodax (Romidepsin)
4.12 Zoladex (Goserelin)
4.13 Cosmegen (Dactinomycin)
4.14 Somatuline Depot (Lanreotide)
4.15 Suprefact (Buserelin)
4.16 Sandostatin (Octreotide Acetate)
4.17 Bynfezia Pen (Octreotide)
4.18 Mepact (Mifamurtide)
4.19 Lutathera (Lutetium Lu 177 dotatate)
4.20 Netspot (Gallium Ga 68 dotatate)


5. Marketed Cancer Peptides Drugs Sales Insight (2019 -2023)
5.1 Lupron
5.2 Kyprolis
5.3 Zoladex
5.4 Lutathera
5.5 Sandostatin
5.6 Somatuline
5.7 Decapeptyl SR
5.8 Velcade
5.9 Ninlaro


6. Global Peptide Cancer Therapeutics Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
6.6 By Drug Formulation


7. Global Peptide Cancer Therapeutics Clinical Trials Insight By Company, Country, Indication & Peptide Segment
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered


8. Marketed Cancer Peptides Clinical Insight by Company, Country & Indication


9. Global Peptide Cancer Therapy Market Dynamics
9.1 Favorable Market Parameters
9.2 Commercialization Challenges


10. Targets for Therapeutic Peptides
10.1 Signal Transduction Pathways
10.2 Cell Cycle Regulation
10.3 Cell Death Pathways
10.4 Tumor Suppressor Protein
10.5 Transcription Factors


11. Peptide Drugs v/s Conventional Cancer Therapeutics
11.1 Peptide v/s Chemotherapy
11.2 Peptide v/s Monoclonal Antibody
11.3 Peptide v/s Gene Therapy
11.4 Peptide v/s Immunotherapy


12. Different Approaches of Peptides in Cancer Therapeutics
12.1 Hormonal Peptides
12.2 Peptide as Radionuclide Drug Carrier
12.3 Peptide Vaccines
12.4 Peptides as Cytotoxic Drug Carrier
12.5 Anticancer Peptides
12.6 Other Anticancer Drugs Closely Related to Peptides


13. Application of Peptides Therapeutics & Detection Methodology by Cancer

13.1 Colorectal Cancer
13.1.1 Peptides in Treatment of Colorectal Cancer
13.1.2 Proprietary Technologies

13.2 Lung Cancer
13.2.1 Peptides in Treatment of Lung Cancer
13.2.2 Proprietary Technologies

13.3 Pancreatic Cancer
13.3.1 Peptide in Treatment of Pancreatic Cancer
13.3.2 Proprietary Technologies

13.4 Gastric Cancer
13.4.1 Peptides in Treatment of Gastric Cancer
13.4.2 Proprietary Technologies

13.5 Breast Cancer
13.5.1 Peptides in Treatment of Breast Cancer
13.5.2 Proprietary Technologies

13.6 Prostate Cancer
13.6.1 Peptides in Treatment of Prostate Cancer
13.6.2 Proprietary Technologies


14. Neoantigen Vaccine: An Emerging Tumor Immunotherapy
14.1 Personalized Neoantigen Based Vaccine in Cancer
14.2 Ongoing Clinical Advancements


15. Venom Peptides: New Era for Cancer Peptide Therapy
15.1 Relevance of Venom Based Peptide Therapeutics
15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides


16. Competitive Landscape
16.1 3B Pharmaceuticals
16.2 AsclepiX Therapeutics
16.3 Bicycle Therapeutics
16.4 Biohaven Labs
16.5 BrightPath Biotherapeutics
16.6 Bristol-Myers Squibb
16.7 Edinburgh Molecular Imaging
16.8 FogPharma
16.9 GE Healthcare
16.10 Gnubiotics Sciences
16.11 Harvard University
16.12 Heidelberg Pharma AG
16.13 IDP Pharma
16.14 Janux Therapeutics
16.15 Medikine
16.16 Modulation Therapeutics
16.17 Novartis
16.18 PeptiDream
16.19 Pharm-Sintez
16.20 Roche
16.21 Sanofi
16.22 Sapience Therapeutics
16.23 Second Genome
16.24 Viewpoint Molecular Targeting
16.25 Vigeo Therapeutics


 



List of Tables

Table 1-1: Source or Chemical Nature of Early Peptides

Table 4-1: Velcade - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma

Table 12-1: Peptides in Clinical Trials

Table 13-1: Peptides & Their Targets in Colorectal Cancer
Table 13-2: Colorectal Cancer – Peptide Based Therapies Currently Under Clinical Trials
Table 13-3: Lung Cancer - Peptide Based Therapies Currently Under Clinical Trials
Table 13-4: Antigens Utilized as Molecular Targets
Table 13-5: Pancreatic Cancer - Peptide Based Therapies Currently Under Clinical Trials
Table 13-6: Gastric Cancer – - Peptide Based Therapies Currently Under Clinical Trials
Table 13-7: Breast Cancer - Peptide Vaccines under Development
Table 13-8: Prostate Cancer – Examples of Therapeutic Peptides

Table 14-1: Global – Late Stage Neoantigen Vaccines

Table 15-1: Other Venom Peptides in Cancer Therapy